Publication Topic

Bean K, Miller B, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285, ISPOR 2023.

Bean K, Olaye A, Miller B, Jensen I, Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408, ISPOR 2023.

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombitant porcine factor VIII or recombitant DVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcomes Res 23(2):225-230.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Substantial burden of illness and mortality in men with adrenomyeloneuropathy. Poster presentation at American Academy of Neurology Annual Meeting, April 2023.

Minshall M, Emden M, McLin R, Kemp P, Pontenani F, Cardosi L, Sacks N. The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US. Poster presentation, ISPOR, April 2023.

Eichler F, Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705. PMID: 36537696.